Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer-Reference-Cited by-同舟云学术

Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

Published:2016-11-18 Issue:12 Volume:25 Page:1405-1412
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Bergamini Alice,Ferrero Simone,Leone Roberti Maggiore Umberto,Scala Carolina,Pella Francesca,Vellone Valerio Gaetano,Petrone Micaela,Rabaiotti Emanuela,Cioffi Raffaella,Candiani Massimo,Mangili Giorgia

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/13543784.2016.1254616

Reference52 articles.

1. The Dualistic Model of Ovarian Carcinogenesis

2. Rethinking ovarian cancer: recommendations for improving outcomes

3. Sorafenib for ovarian cancer

4. The potential of sunitinib as a therapy in ovarian cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy;Journal of Ovarian Research;2024-08-08

2. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-02

3. Therapeutic strategies targeting folate receptor α for ovarian cancer;Frontiers in Immunology;2023-08-30

4. Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer;Frontiers in Pharmacology;2023-03-24

5. Folate Receptor as a Biomarker and Therapeutic Target in Solid Tumors;Current Problems in Cancer;2023-02